← Back to Search

Transdermal System

HP-1050 Patch for Cumulative Irritation and Sensitization Syndrome

Phase 1
Waitlist Available
Research Sponsored by Noven Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 hours
Awards & highlights

Summary

This trial is testing a new skin patch called HP-1050 to see if it causes any skin irritation or allergic reactions. The study involves healthy women.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sensitization Evaluation
Skin Irritation Evaluation

Trial Design

1Treatment groups
Experimental Treatment
Group I: HP-1050 patchExperimental Treatment1 Intervention
HP-1050 and Xulane will be administered simultaneously.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Noven Pharmaceuticals, Inc.Lead Sponsor
8 Previous Clinical Trials
2,339 Total Patients Enrolled
~49 spots leftby Oct 2025